Tandem Diabetes business ‘is just getting going,’ says Lake Street

While the shares of Tandem Diabetes have had a nice move, the business is “just getting going,” Lake Street analyst Brooks O’Neil tells investors in a research note partially titled “Why $100 And How Fast?” The analyst believes Tandem has the best pump on the market today coupled with a pipeline of future products “that will bring market leading innovation to diabetics world-wide over the next few years.” He sees the shares going to $100 and affirms a Buy rating on Tandem Diabetes.
https://thefly.com/landingPageNews.php?id=2875171